心臓バイオマーカーの世界市場:インサイト、市場機会、市場シェア、市場予測

◆英語タイトル:Global Cardiac Biomarkers Market Insights, Opportunity, Analysis, Market Shares And Forecast 2016 – 2022
◆商品コード:OCCAM60714
◆発行会社(調査会社):Occams Research
◆発行日:2016年6月
◆ページ数:140
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD3,900 ⇒換算¥444,600見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD6,900 ⇒換算¥786,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はOccams Research社の日本における正規販売代理店です。Occams Research社の概要及び新刊レポートはこちらでご確認いただけます。
本調査レポートでは、世界の心臓バイオマーカー市場について調査・分析し、市場インサイト、市場機会、市場シェア、市場規模予測などを含め、以下の構成でお届けいたします。
・心臓バイオマーカーの世界市場:イントロダクション
・心臓バイオマーカーの世界市場:市場概観
・心臓バイオマーカーの世界市場:市場動向(促進要因、阻害要因、市場機会)
・心臓バイオマーカーの世界市場:セグメント別市場分析
・心臓バイオマーカーの世界市場:主要地域別市場分析
・心臓バイオマーカーの世界市場:関連企業分析
【レポートの概要】

The global cardiac biomarker market is expected to generate the revenue of $2,225.9 million by 2022, registering a CAGR of 19.5% from 2016 to 2022. The prevention of cardiac diseases, by active monitoring the heart conditions by using cardiac biomarker testing is the newest approach for obtaining fastest output of immediate diagnosing and treatment of cardiac deceases. Cardiac biomarkers are made by protein-based traceable substances used as an indicator to assess biological state and for diagnosing the proactive purposes associated with heart. Cardiac biomarkers are also used as risk calculation for various cardiovascular diseases (CVDs), including myocardial congestive heart failure, infraction, acute coronary syndrome (ACS) among others deceases.

The promising features of markers such as high accuracy, rapid outcomes and affordable pricing of cardiac point of care (POC) testing is supporting the market of cardiac biomarker for the growth, worldwide. To keep the momentum stable of cardiac marker tests, the key manufacturers offers customized solutions. However, limited availability in some cases and side effects such as skeletal muscle injury is hindering the growth of cardiac biomarkers market. However, concerns related to single measurement cardiac biomarkers, high pricing of the devices and certain government regulations is expected to restrain the market to grow.

The global cardiac biomarkers market is basically segmented on the basis of type, application, location of testing and geography. Based on type of cardiac biomarkers, the market is divided into Creatine Kinase (CK-MB), Troponins T and I, myoglobin, BNPs, IMA and others. Troponins I and T are the largest revenue-generating segment in the overall cardiac biomarkers market because of its prodigious specialty and its ability to detect accurately the cardiac events of Acute Coronary Syndrome (ACS).

Based on application segment, the market is subdivided into myocardial infarction, congestive heart failure, atherosclerosis acute coronary syndrome, and others. Myocardial infarction (MI) accounts the highest market share in the global cardiac biomarker market and it is followed by acute coronary syndrome (ACS) because of its highest prevalence rate in all the cardiovascular diseases (CVDs). The location of testing segment is classified under point of care testing and laboratory testing. Doctors and clinicians majorly use point of care cardiac testing for quick monitoring and diagnosing patients with having chest pain in an emergency care unit, therefore, it accounts for the fastest growing CAGR in the forecasted period. However, laboratory testing segment is generating larger revenue in comparison to point of care testing now-a-days.

On the basis of geography, the global cardiac biomarker market is divided into North America, Europe, Asia-Pacific and LAMEA. Out of which North America is leading the global market, owing to the high demand for cardiac testing, high CVD prevalence rates and growing awareness towards cardiac diagnostics solutions. Asia-Pacific is emerging region with fastest growing CAGR due to the modernization in the countries, increasing disposable incomes and increasing affordability for the advanced cardiac treatments.

Key companies working in this market are Roche Diagnostics, Siemens Healthcare, Becton, Alere Inc., BioMerieux, Abbott Laboratories, Bio-Rad Laboratories, Dickinson and Company, Randox laboratories, Beckman Coulter and Thermo Fisher Scientific. Product launch and technological advancements are the few strategies adopted by the key players of global market. Biomarkers production companies are currently focusing on innovative technologies such as automated, multi-assay using combinations of cardiac biomarkers and point-of-care cardiac biomarker devices.

【レポートの目次】

1. INTRODUCTION
1.1. EXECUTIVE SUMMARY
1.2. ESTIMATION METHODOLOGY

2. MARKET OVERVIEW
2.1. MARKET DEFINITION AND SCOPE
2.2. KEY FINDINGS
2.3. PARAMETRIC ANALYSIS
2.4. KEY MARKET INSIGHTS
2.4.1. TOP 3 EMERGING COUNTRIES
2.4.2. TOP 3 REVENUE GENERATING SEGMENTS
2.4.3. TOP GROWING MARKETS AND EMERGING TRENDS
2.4.4. TOP 3 GEOGRAPHY
2.5. COMPETITIVE LANDSCAPE
2.5.1. MARKET SHARE ANALYSIS
2.5.2. TOP WINNING STRATEGIES
2.5.3. CASE STUDIES: TOP COMPETITIVE MOVES
2.6. PORTER’S FIVE FORCE MODEL
2.6.1. THREAT OF NEW ENTRANTS
2.6.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
2.6.3. BARGAINING POWER OF BUYER
2.6.4. BARGAINING POWER OF SUPPLIER
2.6.5. INTENSITY OF COMPETITIVE RIVALRY
2.7. KEY BUYING CRITERIA
2.8. STRATEGIC RECOMMENDATION
2.9. STRATEGIC CONCLUSIONS

3. MARKET DETERMINANTS
3.1. MARKET DRIVERS
3.1.1. RISING PREVALENCE OF CARDIOVASCULAR DISEASES
3.1.2. COST EFFECTIVE DEVICE
3.1.3. NON-INVASIVE METHOD
3.1.4. ACCURACY IN PREDICTION
3.1.5. HELPFUL IN CLINICAL TRIALS
3.1.6. MULTI-APPLICATION
3.1.7. TECHNOLOGICAL ADVANCEMENTS USING CARDIAC BIOMARKERS COMBINATIONS
3.1.8. INCREASING POINT OF CARE (POC) APPLICATION
3.2. MARKET RESTRAINTS
3.2.1. GOVERNMENT REGULATIONS
3.2.2. CONFIRMATION IN RESULT
3.2.3. COMPLEX PRODUCTION PROCESS
3.3. MARKET OPPORTUNITIES
3.3.1. DEMAND OF PERSONALIZED MEDICINE
3.3.2. POINT OF CARE (POC) TESTING USING CARDIAC BIOMARKERS
3.3.3. FUTURE DEVELOPMENTS IN NOVEL CARDIAC BIOMARKERS
3.4. MARKET CHALLENGES
3.4.1. APPROVAL CLINICAL VALIDITY AND UTILITY OF BIOMARKERS-BASED TESTS
3.5. PARENT MARKET
3.6. COMPETITORS MARKET
3.7. ALTERNATIVE MARKET

4. MARKET SEGMENTATION
4.1. BY LOCATION OF TESTING
4.1.1. POINT OF CARE
4.1.2. LABORATORY TESTING
4.2. BY TYPE
4.2.1. CREATINE KINASE (CK-MB)
4.2.2. TROPONINS(T,I)
4.2.3. MYOGLOBIN
4.2.4. NATRIURETIC PEPTIDES (BNP AND NT-PROBNP)
4.2.5. ISCHEMIA MODIFIED ALBUMIN
4.2.6. OTHERS
4.3. BY APPLICATION
4.3.1. MYOCARDIAL INFARCTION
4.3.2. CONGESTIVE HEART FAILURE
4.3.3. ACUTE CORONARY SYNDROME
4.3.4. ATHEROSCLEROSIS
4.3.5. OTHERS

5. GEOGRAPHICAL ANALYSIS
5.1. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.1.1. UNITED STATES (U.S.) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.1.2. CANADA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.2. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.2.1. UNITED KINGDOM (UK) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.2.2. FRANCE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.2.3. GERMANY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.2.4. SPAIN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.2.5. ITALY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.2.6. ROE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.3. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.3.1. INDIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.3.2. CHINA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.3.3. JAPAN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.3.4. KOREA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.3.5. AUSTRALIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.3.6. ROAPAC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.4. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.4.1. LATIN AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.4.2. MENA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
5.4.3. AFRICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)

6. COMPANY PROFILE
1. ABBOTT DIAGNOSTICS
2. ALERE INC.
3. BECKMAN COULTER
4. BECTON, DICKINSON AND CO.
5. BG MEDICINE INC.
6. BIOMERIEUX
7. EKF DIAGNOSTICS HOLDINGS, INC.
8. MERCK & CO, INC.
9. RADIOMETER MEDICAL
10. RANDOX LABORATORY
11. RESPONSE BIOMEDICAL
12. ROCHE HOLDING AG
13. SIEMENS HEALTHCARE
14. SINGULEX
15. THERMO FISHER SCIENTIFIC

LIST OF TABLES
1. GLOBAL CARDIAC BIOMARKERS MARKET BY LOCATION OF TESTING 2014-2022 ($ MILLION)
2. GLOBAL CARDIAC BIOMARKERS MARKET BY POINT OF CARE 2014-2022 ($ MILLION)
3. GLOBAL CARDIAC BIOMARKERS MARKET BY LABORATORY TESTING 2014-2022 ($ MILLION)
4. GLOBAL CARDIAC BIOMARKERS MARKET BY TYPE 2014-2022 ($ MILLION)
5. GLOBAL CARDIAC BIOMARKERS MARKET BY CREATINE KINASE (CK-MB) 2014-2022 ($ MILLION)
6. GLOBAL CARDIAC BIOMARKERS MARKET BY TROPONINS(T,I) 2014-2022 ($ MILLION)
7. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOGLOBIN 2014-2022 ($ MILLION)
8. GLOBAL CARDIAC BIOMARKERS MARKET BY NATRIURETIC PEPTIDES (BNP AND NT-PROBNP) 2014-2022 ($ MILLION)
9. GLOBAL CARDIAC BIOMARKERS MARKET BY ISCHEMIA MODIFIED ALBUMIN 2014-2022 ($ MILLION)
10. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
11. GLOBAL CARDIAC BIOMARKERS MARKET BY APPLICATION 2014-2022 ($ MILLION)
12. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOCARDIAL INFARCTION 2014-2022 ($ MILLION)
13. GLOBAL CARDIAC BIOMARKERS MARKET BY CONGESTIVE HEART FAILURE 2014-2022 ($ MILLION)
14. GLOBAL CARDIAC BIOMARKERS MARKET BY ACUTE CORONARY SYNDROME 2014-2022 ($ MILLION)
15. GLOBAL CARDIAC BIOMARKERS MARKET BY ATHEROSCLEROSIS 2014-2022 ($ MILLION)
16. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
17. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
18. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
19. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
20. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)

LIST OF FIGURES
1. GLOBAL CARDIAC BIOMARKERS MARKET BY POINT OF CARE 2014-2022 ($ MILLION)
2. GLOBAL CARDIAC BIOMARKERS MARKET BY LABORATORY TESTING 2014-2022 ($ MILLION)
3. GLOBAL CARDIAC BIOMARKERS MARKET BY CREATINE KINASE (CK-MB) 2014-2022 ($ MILLION)
4. GLOBAL CARDIAC BIOMARKERS MARKET BY TROPONINS(T,I) 2014-2022 ($ MILLION)
5. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOGLOBIN 2014-2022 ($ MILLION)
6. GLOBAL CARDIAC BIOMARKERS MARKET BY NATRIURETIC PEPTIDES (BNP AND NT-PROBNP) 2014-2022 ($ MILLION)
7. GLOBAL CARDIAC BIOMARKERS MARKET BY ISCHEMIA MODIFIED ALBUMIN 2014-2022 ($ MILLION)
8. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
9. GLOBAL CARDIAC BIOMARKERS MARKET BY MYOCARDIAL INFARCTION 2014-2022 ($ MILLION)
10. GLOBAL CARDIAC BIOMARKERS MARKET BY CONGESTIVE HEART FAILURE 2014-2022 ($ MILLION)
11. GLOBAL CARDIAC BIOMARKERS MARKET BY ACUTE CORONARY SYNDROME 2014-2022 ($ MILLION)
12. GLOBAL CARDIAC BIOMARKERS MARKET BY ATHEROSCLEROSIS 2014-2022, ($ MILLION)
13. GLOBAL CARDIAC BIOMARKERS MARKET BY OTHERS 2014-2022 ($ MILLION)
14. NORTH AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
15. UNITED STATES (U.S.) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
16. CANADA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
17. EUROPE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
18. UNITED KINGDOM (UK) CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
19. FRANCE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
20. GERMANY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
21. SPAIN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
22. ITALY CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
23. ROE CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
24. ASIA PACIFIC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
25. INDIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
26. CHINA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
27. JAPAN CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
28. KOREA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
29. AUSTRALIA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
30. ROAPAC CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
31. REST OF THE WORLD CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
32. LATIN AMERICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
33. MENA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)
34. AFRICA CARDIAC BIOMARKERS MARKET 2014-2022 ($ MILLION)



【レポートのキーワード】

心臓バイオマーカー、ポイントオブケア、クレアチンキナーゼ、心筋梗塞

★調査レポート[心臓バイオマーカーの世界市場:インサイト、市場機会、市場シェア、市場予測]販売に関する免責事項
★調査レポート[心臓バイオマーカーの世界市場:インサイト、市場機会、市場シェア、市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆